Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
04:38pm, Thursday, 13'th Jul 2023
Warren said the report shows that Congress needs to take additional steps to reduce the excessive prices of insulin from Eli Lilly, Sanofi and Novo Nordisk.
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
01:37pm, Thursday, 13'th Jul 2023
An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.
Uninsured US patients pay up to $330 for Eli Lilly's $25 insulin, Senator Warren says
07:03am, Thursday, 13'th Jul 2023
Americans without health insurance pay an average of $98 for Eli Lilly's generic insulin despite the company's May 1 pledge to cut its list price to $25 per vial, according to a survey of more than 30
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
03:59pm, Wednesday, 12'th Jul 2023
The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts s
EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm
01:34pm, Tuesday, 11'th Jul 2023
The European Medicines Agency said Tuesday it's reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines called GLP-1 receptor agonists, that are used t
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
10:00am, Tuesday, 11'th Jul 2023
INDIANAPOLIS , July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will be
3 Reasons to Buy Eli Lilly, and 1 Reason to Sell
05:34am, Tuesday, 11'th Jul 2023
Eli Lilly's prospective drugs and existing obesity/diabetes medicines are strong. The company's dividend has lots of room for growth.
Ozempic and other weight loss drugs are 'upending the entire idea' of weight loss, reporter says
01:10pm, Monday, 10'th Jul 2023
Nathan Bomey, Axios Business Reporter and Co-author of the Axios Closer Newsletter, joins Yahoo Finance Live anchors Julie Hyman and Brad Smith to discuss the popularity of prescription weight loss dr
Eli Lilly: Patients Get Skinnier, Profits Get Fatter
04:49am, Monday, 10'th Jul 2023
Eli Lilly has seen a massive ramp-up in its diabetes, or better said weight loss, drug Mounjaro. Investors continue to price in further advancements on this front; the question is how much is priced i
Obesity Drugs Won't Starve These Other Potential Blockbusters
08:00am, Friday, 07'th Jul 2023
Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly's medication were published last week.
Can Eli Lilly's (LLY) Continue its Ride on Obesity Drug Wave?
11:32am, Wednesday, 05'th Jul 2023
Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.
Verve: Exciting Deal With Eli Lilly, But Still Neutral (Reiterating Hold)
04:57am, Tuesday, 04'th Jul 2023
Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the FDA's clinical hold on Verve's PCSK9 candidate VE
Eli Lilly Could Be Making The Next Ozempic, but Should You Buy the Stock?
08:15am, Sunday, 02'nd Jul 2023
Eli Lilly is working on a molecule that might be better than Novo Nordisk's Ozempic. It already has another medicine on the market that could be better.
Eli Lilly: Miracle Drug Progress Offers Shareholders More Upside
10:23pm, Friday, 30'th Jun 2023
Eli Lilly and Company continues to make impressive progress when it comes to its obesity and diabetes medications. Shares have already shot up in recent months because of this, but this is likely the
The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023
12:39pm, Friday, 30'th Jun 2023
Pharmaceutical stocks have not shared in this year's bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%.
